JFL Life Sciences Ltd
JFLLIFE NSE
JFL Life Sciences Ltd
HealthcareNSE: JFLLIFE Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹91.40 Cr
Volatility
High Risk
P/E Ratio
12.82
EBITDA
₹11.71 Cr
Return on Equity
10.54%
Debt to Equity
0.48
Book Value
₹13.9
52W High
₹15.4
52W Low
₹8.55
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view JFL Life Sciences Ltd insights
29 extracted metrics + investor summaries across FY19–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
3- Company is expected to give good quarter
- Company has delivered good profit growth of 64.0% CAGR over last 5 years
- Company's working capital requirements have reduced from 136 days to 103 days
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.2% over last 3 years.
Growth Rate
Revenue Growth
60.02% ↗
Net Income Growth
53.33% ↗
Cash Flow Change
-142.22% ↘
ROE
13.58% ↗
ROCE
38.94% ↗
EBITDA Margin (Avg.)
-10.90% ↗
Quarterly Results
| Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.7 | 9.54 | 39.51 | 21.25 | 11.73 | 11.59 | 29.91 | 26.84 | 63.05 | 11.1 |
| Expenses | 20.15 | 6.48 | 37.1 | 19.9 | 10.35 | 9.66 | 27 | 23.49 | 59.54 | 9.01 |
| Operating Profit | 1.55 | 3.06 | 2.41 | 1.35 | 1.38 | 1.93 | 2.91 | 3.35 | 3.51 | 2.09 |
| OPM % | 7.14% | 32.08% | 6.1% | 6.35% | 11.76% | 16.65% | 9.73% | 12.48% | 5.57% | 18.83% |
| Other Income | 0.02 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.04 | 0.02 |
| Interest | 0.09 | 0.26 | 0.27 | 0.2 | 0.33 | 0.24 | 0.44 | 0.38 | 1.03 | 0.3 |
| Depreciation | 0.11 | 0.24 | 0.24 | 0.16 | 0.36 | 0.26 | 0.27 | 0.27 | 0.27 | 0.32 |
| PBT | 1.37 | 2.56 | 1.9 | 0.99 | 0.69 | 1.43 | 2.21 | 2.71 | 2.25 | 1.49 |
| Tax % | 13.14% | 25.39% | 23.16% | 25.25% | 86.96% | 48.25% | 10.86% | 25.09% | 26.22% | 25.5% |
| Net Profit | 1.19 | 1.91 | 1.45 | 0.74 | 0.08 | 0.75 | 1.97 | 2.02 | 1.66 | 1.11 |
| EPS in Rs | 0.18 | 0.29 | 0.22 | 0.11 | 0.01 | 0.11 | 0.3 | 0.31 | 0.25 | 0.17 |
Profit & Loss
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 32 | 30 | 33 | 34 | 43 | 47 | 82 | 131 | 131 |
| Expenses | 30 | 28 | 31 | 28 | 39 | 42 | 74 | 120 | 119 |
| Operating Profit | 1 | 2 | 2 | 5 | 4 | 5 | 8 | 12 | 12 |
| OPM % | 4.2% | 6% | 7% | 16% | 9% | 10% | 10% | 9% | 9% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| PBT | 0 | 0 | 1 | 4 | 4 | 4 | 6 | 9 | 9 |
| Tax % | 28% | 29% | 27% | 26% | 25% | 13% | 32% | 26% | — |
| Net Profit | 0 | 0 | 1 | 3 | 3 | 3 | 4 | 6 | 7 |
| EPS in Rs | 1.25 | 1.5 | 1.5 | 0.59 | 0.43 | 0.5 | 0.63 | 0.97 | 1.03 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 8% | 0% | 0% | — |
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.5 | 8 | 11 | 11 | 33 | 33 |
| Reserves | 5 | 5 | 6 | 3 | 21 | 25 | 6 | 13 |
| Borrowings | 8 | 9 | 17 | 16 | 7 | 6 | 11 | 22 |
| Other Liabilities | 3 | 10 | 5 | 21 | 10 | 15 | 22 | 39 |
| Total Liabilities | 16 | 24 | 29 | 48 | 49 | 57 | 72 | 106 |
| Fixed Assets | 2 | 5 | 6 | 7 | 7 | 12 | 12 | 15 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 14 | 19 | 23 | 41 | 42 | 44 | 60 | 92 |
| Total Assets | 16 | 24 | 29 | 48 | 49 | 57 | 72 | 106 |
Cash Flow
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating | -3 | 3 | -6 | 2 | -9 | 8 | -4 | -4 |
| Investing | -1 | -3 | -2 | -1 | 1 | -6 | 0 | -4 |
| Financing | 4 | 0 | 7 | -1 | 8 | -2 | 4 | 9 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Free Cash Flow | -4 | 0 | -8 | 1 | -9 | 2 | -4 | -8 |
| CFO/OP | -225 | 177 | -268 | 41 | -206 | 185 | -31 | -37 |
Ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 153 | 132 | 215 | 192 | 197 | 155 | 148 |
| Inventory Days | 21 | 52 | 72 | 212 | 130 | 149 | 128 | 110 |
| Days Payable | 18 | 122 | 58 | 218 | 76 | 92 | 98 | 93 |
| Cash Conversion Cycle | 115 | 83 | 146 | 208 | 246 | 254 | 186 | 165 |
| Working Capital Days | 62 | 7 | 74 | 117 | 221 | 181 | 124 | 103 |
| ROCE % | — | 12% | 10% | 23% | 15% | 11% | 16% | 18% |
Documents
1
Outcome of Board Meeting
10 Aug - Board approved unaudited Q1 FY27 results on August 10, 2026; net profit was Rs 111.37 lakh. 10 Aug - Board approved unaudited Q1 FY27 results on August 10, 2026; net profit was Rs 111.37 lakh.
2
Copy of Newspaper Publication
1 Aug - Published newspaper notice for shareholder meeting on August 1, 2026 in Financial Express English and Gujarati. 1 Aug - Published newspaper notice for shareholder meeting on August 1, 2026 in Financial Express English and Gujarati.
3
Shareholders meeting
31 Jul - Integrated Annual Report FY2025-26 and AGM notice for August 25, 2026; director reappointments proposed. 31 Jul - Integrated Annual Report FY2025-26 and AGM notice for August 25, 2026; director reappointments proposed.
4
Certificate under SEBI (Depositories and Participants) Regulations, 2018
3 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026. 3 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.
5
Trading Window
26 Jun - Trading window closed from 1 July 2026 until 48 hours after Q1 FY27 results. 26 Jun - Trading window closed from 1 July 2026 until 48 hours after Q1 FY27 results.
Frequently Asked Questions about JFL Life Sciences Ltd
What does JFL Life Sciences Ltd do?
Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations[1]
Where is JFL Life Sciences Ltd (JFLLIFE) listed?
JFL Life Sciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: JFLLIFE. You can view its live share price, financials, and ratios on Tapetide.
Which sector does JFL Life Sciences Ltd belong to?
JFL Life Sciences Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of JFL Life Sciences Ltd?
JFL Life Sciences Ltd has a market capitalisation of approximately ₹91.40 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of JFL Life Sciences Ltd?
The Price-to-Earnings (PE) ratio of JFL Life Sciences Ltd is 12.82. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of JFL Life Sciences Ltd?
Over the past 52 weeks, JFL Life Sciences Ltd has traded between a low of ₹8.55 and a high of ₹15.4. This range helps investors understand the stock's price volatility and recent trading levels.
Does JFL Life Sciences Ltd pay dividends?
Yes, JFL Life Sciences Ltd has a dividend yield of 1.81%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of JFL Life Sciences Ltd?
JFL Life Sciences Ltd has a Return on Equity (ROE) of 10.54%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research JFL Life Sciences Ltd on Tapetide?
On Tapetide, you can view JFL Life Sciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations[1]